Table 1.
Cohort characteristics
| CT Cau (N=53) | CT AA (N=52) | p – valuea | AD Cau (N=47) | AD AA (N=51) | p – valuea | |
|---|---|---|---|---|---|---|
| Characteristics | ||||||
| Sex | 33 F, 20 M | 33 F, 19 M | - | 29 F, 18 M | 32 F, 19 M | - |
| Ageb | 65 ± 8 | 64 ± 8 | 0.8848 | 68 ± 9 | 68 ± 9 | 0.9998 |
| MoCAc | 26 ± 2 | 25 ± 3 | 0.7559 | 16 ± 6 | 14 ± 6 | 0.2055 |
| *Aβ42d | 1195.2 ± 262.0 | 1021.4 ± 301.1 | 0.0021 | 558.2 ± 169.9 | 483.4 ± 151.8 | 0.4026 |
| tTaud | 186.2 ± 61.6 | 158.5 ± 56.5 | 0.6573 | 423.7 ± 189.2 | 301.5 ± 134.8 | < 0.0001 |
| pTau181d | 16.6 ± 5.6 | 14.1 ± 4.9 | 0.7787 | 43.3 ± 20.8 | 30.1 ± 14.1 | < 0.0001 |
| tTau/Aβ42 d | 0.14 ± 0.03 | 0.14 ± 0.03 | 0.9994 | 0.78 ± 0.31 | 0.66 ± 0.30 | 0.0850 |
Abbreviations: CT Control, AD Alzheimer’s disease, Cau Caucasian / White, AA African American / Black
ap-values were calculated using one-way ANOVA with Tukey correction, bold indicates p < 0.05
bAge in years. Values given as average ± standard deviation
cMost recent Montreal Cognitive Assessment (MoCA) score. Values given as average ± standard deviation
dAβ42, tTau, pTau181, and tTau/Aβ42 in pg/mL. Values given as average ± standard deviation
*Aβ42 levels that reached saturation (1700 pg / mL) were excluded from calculations and analysis